India’s pharmaceutical medicine COVID-19, developed by AstraZeneca and Oxford University, is a two-pronged approach to innovation in two countries. The Minister for Publicity and Publicity, Prakash Javadekar, told people on Saturday that he was recovering from a stroke and was helping to recover from his injuries on Friday, according to Reuters.

It is the first COVID-19 drug to support the shadow of India, which has a long-standing belief that double-digit disease progression at any time in the United States, na-thirty the country is gaining public view speed for drug delivery. Javadekar said at least some traditional medicine is waiting for support – Bharat Biotch’s COVAXIN, Zydus Cadila’s ZyCoV-D, and Sputnik-V Russia.

Wound, “India has the potential if the whole country there is at least one drug-supported medicine.” “We distributed a piece of paper yesterday, Serum’s COVISHIELD,” he said, referring to the excitement that the AstraZeneca / Oxford shooting was being carried out in the area by the public Serum of India (SII). The Endowment Institute in India is in the process of developing a plan and information for others to write the yen. SII documentation for peak frequency regulation seems to be 28 days apart.

AstraZeneca / Oxford, which was commissioned by Britain on Tuesday, is a dream come true for some of the best – the best of the best. It seems, however, that the stress of the crisis has stemmed from its well-known elimination strategies as well as the fact that it was published in November that the next-generation pharmaceutical supplement created all the top 90-percent of the furniture. it should be two people higher. percent di iyè.